Clinical trial

Alisertib (MLN8237) in Combination With Weekly Paclitaxel in East Asian Patients With Advanced Solid Tumors

NCT02367352

StatusTERMINATED

Study typeINTERVENTIONAL

Start date2015-03-19

PhasePHASE1

Study timeline

Study start (actual)2015-03-19Date precision: day

Registry last updated2019-06-26

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Advanced Solid Tumorsunresolved

Ovarian Cancerunresolved

Small Cell Lung Cancerunresolved

Interventions

AlisertibDRUG

PaclitaxelDRUG · verified · RxNorm: paclitaxel

Sponsors & collaborators

Millennium Pharmaceuticals, Inc.lead sponsor

Mapped research locations

SeoulSouth Korea1 ChibaJapan1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT02367352 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.